Publication related to RSI or an RSI staff member
Differentiating Carotid Free-Floating Thrombus From Atheromatous Plaque Using Intraluminal Filling Defect Length on CTA: A Validation Study.
Authors
- Torres, Carlos, Torres C, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada. catorres@toh.ca.
- Lum, Cheemun, Lum C, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Puac-Polanco, Paulo, Puac-Polanco P, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Stotts, Grant, Stotts G, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Shamy, Michel Christopher Frank, Shamy MCF, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Blacquiere, Dylan, Blacquiere D, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Lun, Ronda, Lun R, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Dave, Prasham, Dave P, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Bharatha, Aditya, Bharatha A, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Menon, Bijoy K, Menon BK, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Thornhill, Rebecca, Thornhill R, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Momoli, Franco, Momoli F, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
- Dowlatshahi, Dar, Dowlatshahi D, From the Division of Neuroradiology (C.T., P.P.-P.), Department of Radiology, Division of Neurology (G.S., M.C.F.S., D.B., R.L., P.D., D.D.), Department of Medicine, Division of Medical Physics (R.T.), Department of Radiology, and School of Epidemiology and Public Health (F.M.), University of Ottawa; Neuroscience Program (C.T., G.S., M.C.F.S., D.B., D.D.), The Ottawa Hospital Research Institute; Division of Neuroradiology (A.B.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Ontario; and Departments of Clinical Neurosciences, Radiology, and Community Health Sciences (B.K.M.), University of Calgary, Foothills Medical Centre, Alberta, Canada.
YEAR OF PUBLICATION: 2021
SOURCE: Neurology. 2021 Aug 24;97(8):e785-e793. doi: 10.1212/WNL.0000000000012368. Epub 2021 Jun 14.
JOURNAL TITLE ABBREVIATION: Neurology
JOURNAL TITLE: Neurology
ISSN: 1526-632X (Electronic) 0028-3878 (Linking)
VOLUME: 97
ISSUE: 8
PAGES: e785-e793
PLACE OF PUBLICATION: United States
ABSTRACT:
OBJECTIVE: To validate a previously proposed filling defect length threshold of >3.8 mm on CT angiography (CTA) to discriminate between free-floating thrombus (FFT) and plaque of atheroma. METHODS: This was a prospective multicenter observational study of 100 participants presenting with TIA/stroke symptoms and a carotid intraluminal filling defect on initial CTA. Follow-up CTA was obtained within 1 week and at weeks 2 and 4 if the intraluminal filling defect was unchanged in length. Resolution or decreased length was diagnostic of FFT, whereas its static appearance after 4 weeks was indicative of plaque. Diagnostic accuracy of FFT length was assessed by receiver operating characteristic analysis. RESULTS: Ninety-five participants (mean [SD] age 68 [13] years, 61 men, 83 participants with FFT, 12 participants with a plaque) were evaluated. The >3.8-mm threshold had a sensitivity of 88% (73 of 83) (95% confidence interval [CI] 78%-94%) and specificity of 83% (10 of 12) (95% CI 51%-97%) (area under the curve 0.91, p < 0.001) for the diagnosis of FFT. The optimal length threshold was >3.64 mm with a sensitivity of 89% (74 of 83) (95% CI 80%-95%) and specificity of 83% (10 of 12) (95% CI 51%-97%). Adjusted logistic regression showed that every 1-mm increase in intraluminal filling defect length is associated with an increase in odds of FFT of 4.6 (95% CI 1.9-11.1, p = 0.01). CONCLUSION: CTA enables accurate differentiation of FFT vs plaque using craniocaudal length thresholds. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02405845. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with TIA/stroke symptoms, the presence of CTA-identified filling defects of lengths >3.8 mm accurately discriminates FFT from atheromatous plaque.
OBJECTIVE: To validate a previously proposed filling defect length threshold of >3.8 mm on CT angiography (CTA) to discriminate between free-floating thrombus (FFT) and plaque of atheroma. METHODS: This was a prospective multicenter observational study of 100 participants presenting with TIA/stroke symptoms and a carotid intraluminal filling defect on initial CTA. Follow-up CTA was obtained within 1 week and at weeks 2 and 4 if the intraluminal filling defect was unchanged in length. Resolution or decreased length was diagnostic of FFT, whereas its static appearance after 4 weeks was indicative of plaque. Diagnostic accuracy of FFT length was assessed by receiver operating characteristic analysis. RESULTS: Ninety-five participants (mean [SD] age 68 [13] years, 61 men, 83 participants with FFT, 12 participants with a plaque) were evaluated. The >3.8-mm threshold had a sensitivity of 88% (73 of 83) (95% confidence interval [CI] 78%-94%) and specificity of 83% (10 of 12) (95% CI 51%-97%) (area under the curve 0.91, p < 0.001) for the diagnosis of FFT. The optimal length threshold was >3.64 mm with a sensitivity of 89% (74 of 83) (95% CI 80%-95%) and specificity of 83% (10 of 12) (95% CI 51%-97%). Adjusted logistic regression showed that every 1-mm increase in intraluminal filling defect length is associated with an increase in odds of FFT of 4.6 (95% CI 1.9-11.1, p = 0.01). CONCLUSION: CTA enables accurate differentiation of FFT vs plaque using craniocaudal length thresholds. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02405845. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with TIA/stroke symptoms, the presence of CTA-identified filling defects of lengths >3.8 mm accurately discriminates FFT from atheromatous plaque.
COPYRIGHT INFORMATION: (c) 2021 American Academy of Neurology.
LANGUAGE: eng
DATE OF PUBLICATION: 2021 Aug 24
DATE OF ELECTRONIC PUBLICATION: 20210614
DATE COMPLETED: 20210903
DATE REVISED: 20210903
MESH DATE: 2021/09/04 06:00
EDAT: 2021/08/25 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1212/WNL.0000000000012368 [doi]
SECONDARY SOURCE ID: ClinicalTrials.gov/NCT02405845
OWNER: NLM
Related RSI Experts
Vice-President Chemical and Product Safety
Dr. Franco Momoli joined Risk Sciences International (RSI) in 2019 and currently serves as Vice-President, Chemical and Product Safety. In this role, he leads a multidisciplinary team of epidemiologists, risk assessors, toxicologists, and biostatisticians in conducting human health risk assessments...